Highly rated in
Highly rated in
Check Dr. Yazmin Odia's experience treating your condition:
About Dr. Yazmin Odia

Yazmin Odia is a Neurologist in Miami, Florida. Odia has been practicing medicine for over 16 years and is highly rated in 18 conditions, according to our data. Her top areas of expertise are Glioma, Brain Tumor, Metastatic Brain Tumor, and Glioblastoma. She is licensed to treat patients in Florida. Odia is currently accepting new patients.

Her clinical research consists of co-authoring 45 peer reviewed articles and participating in 7 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Yazmin Odia it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Yazmin Odia accepts the following insurance:

  •  Ambetter
  •  Bright Health
  •  Molina Healthcare
  •  Cigna
  •  Aetna
  •  AvMed

Call to see if your plan is accepted.
8900 N Kendall Dr, Miami, FL 33176
Background & Education
Graduate Institution
Other, 2006
Psychiatry & Neurology in FL
Hospital Affiliations
Baptist Hospital
Homestead Hospital
Doctors Hospital
West Kendall Baptist Hospital
Mariners Hospital
South Miami Hospital
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas
Oral ONC201 in Recurrent Glioblastoma, H3 K27M-mutant Glioma, and Diffuse Midline Glioma
A Phase I/II Trial of Combination Tumor Treating Fields, Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
View 5 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors